Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amgen (AMGN)
NASDAQ:AMGN
Amgen (AMGN) Stock Price & Analysis
5,471 Followers
AMGN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$206.75 - $327.16
Previous Close$264.07
Volume445.62K
Average Volume (3M)2.93M
Market Cap
$141.75B
Enterprise Value$195.19B
Total Cash (Recent Filing)$10.94B
Total Debt (Recent Filing)$64.61B
Price to Earnings (P/E)21.1
Beta0.49
Next Earnings
May 02, 2024EPS Estimate
$3.89Next Dividend Ex-Date
May 16, 2024Dividend Yield3.25%
Share Statistics
EPS (TTM)12.48
Shares Outstanding535,918,901
10 Day Avg. Volume2,055,609
30 Day Avg. Volume2,934,121
Standard Deviation0.07
R-Squared0.17
Alpha0.00511
Financial Highlights & Ratios
Price to Book (P/B)-3.16
Price to Sales (P/S)5.02
Price to Cash Flow (P/CF)66.20
P/FCF Ratio32.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.92
Enterprise Value/Gross Profit9.89
Enterprise Value/Ebitda13.19
Forecast
1Y Price Target
$309.24Price Target Upside16.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
Amgen News
PremiumPress Releases
AMGEN ANNOUNCES 2024 SECOND QUARTER DIVIDEND
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentAMGN exhibits confidence in advancing Tezspire's development, with plans for Phase III trials targeting patients with high eosinophil counts, which could translate into a larger market reach and increased stock value.
Drug EfficacyTezspire demonstrates a significant reduction in COPD exacerbation rates, especially in patients with elevated eosinophil counts, suggesting a strong competitive edge in treatment effectiveness.
Market PotentialWith the potential to address a broader COPD patient population and a substantial market opportunity, Tezspire could become a leading treatment, offering improved convenience with less frequent dosing.
Bears Say
Competitive LandscapeCompetition in the obesity market is intensifying, with LLY and Novo leading and improving the standard of care.
Drug EfficacyThe overall phase 2 trial for Tezspire missed the primary endpoint, which might raise concerns about its efficacy.
Investor SentimentInvestor confidence in MariTide may be shaken due to the robustness of VK2735's trial results and its implications on market positioning.
---
Ownership Overview
1.08% Insiders
21.25% Mutual Funds
27.31% Other Institutional Investors
50.36% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AMGN FAQ
What was Amgen’s price range in the past 12 months?
Amgen lowest stock price was $206.75 and its highest was $327.16 in the past 12 months.
What is Amgen’s market cap?
Currently, no data Available
When is Amgen’s upcoming earnings report date?
Amgen’s upcoming earnings report date is May 02, 2024 which is in 14 days.
How were Amgen’s earnings last quarter?
Amgen released its earnings results on Feb 06, 2024. The company reported $4.71 earnings per share for the quarter, beating the consensus estimate of $4.591 by $0.119.
Is Amgen overvalued?
According to Wall Street analysts Amgen’s price is currently Undervalued.
Does Amgen pay dividends?
Amgen pays a Quarterly dividend of $2.25 which represents an annual dividend yield of 3.25%. See more information on Amgen dividends here
What is Amgen’s EPS estimate?
Amgen’s EPS estimate is $3.89.
How many shares outstanding does Amgen have?
Amgen has 535,918,900 shares outstanding.
What happened to Amgen’s price movement after its last earnings report?
Amgen reported an EPS of $4.71 in its last earnings report, beating expectations of $4.591. Following the earnings report the stock price went down -6.39%.
Which hedge fund is a major shareholder of Amgen?
Among the largest hedge funds holding Amgen’s share is PRIMECAP Management Co. It holds Amgen’s shares valued at 4B.
---
Amgen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$309.24 (16.91% Upside)
$309.24 (16.91% Upside)
Blogger Sentiment
Bullish
AMGN Sentiment 88%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 219.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days <0.1%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.03%
12-Months-Change
Fundamentals
Return on Equity
135.79%
Trailing 12-Months
Asset Growth
49.19%
Trailing 12-Months
Company Description
Amgen
Founded in 1980, California-based Amgen, Inc. is one of the world's leading biotechnology companies, which is engaged in the discovery, development, manufacture and marketing of human therapeutics. It primarily focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas.
---
AMGN Company Deck
---
AMGN Earnings Call
Q4 2024
0:00 / 0:00
---
AMGN Revenue Breakdown
14.36% Prolia
13.11% Enbrel
7.76% Otezla
7.49% XGEVA
57.27% Other
---
AMGN Stock 12 Months Forecast
Average Price Target
$309.24
▲(16.91% Upside)
Technical Analysis
Best Analysts Covering AMGN
1 Year
1 Year Success Rate
20/27 ratings generated profit
1 Year Average Return
+14.67%
reiterated a buy rating 4 days ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 74.07% of your transactions generating a profit, with an average return of +14.67% per trade.
---